armata pharmaceuticals - ARMP

ARMP

Close Chg Chg %
13.64 -0.51 -3.74%

Open Market

13.13

-0.51 (3.74%)

Volume: 15.09K

Last Updated:

Apr 24, 2026, 10:57 AM EDT

Company Overview: armata pharmaceuticals - ARMP

ARMP Key Data

Open

$13.53

Day Range

12.87 - 13.55

52 Week Range

1.17 - 16.34

Market Cap

$542.17M

Shares Outstanding

36.63M

Public Float

11.11M

Beta

1.40

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$4.79

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

50.97K

 

ARMP Performance

1 Week
 
17.65%
 
1 Month
 
61.65%
 
3 Months
 
125.50%
 
1 Year
 
852.82%
 
5 Years
 
226.81%
 

ARMP Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About armata pharmaceuticals - ARMP

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

ARMP At a Glance

Armata Pharmaceuticals, Inc.
5005 McConnell Avenue
Los Angeles, California 90066
Phone 1-310-665-2928 Revenue 4.90M
Industry Biotechnology Net Income -173,799,000.00
Sector Health Technology Employees 61
Fiscal Year-end 12 / 2026
View SEC Filings

ARMP Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 46.408
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -17.073
Enterprise Value to Sales 103.367
Total Debt to Enterprise Value 0.568

ARMP Efficiency

Revenue/Employee 80,393.443
Income Per Employee -2,849,163.934
Receivables Turnover 10.39
Total Asset Turnover 0.053

ARMP Liquidity

Current Ratio 1.192
Quick Ratio 1.192
Cash Ratio 0.971

ARMP Profitability

Gross Margin 68.781
Operating Margin -636.664
Pretax Margin -3,544.025
Net Margin -3,544.025
Return on Assets -187.363
Return on Equity N/A
Return on Total Capital -250.351
Return on Invested Capital -347.706

ARMP Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 414.88
Total Debt to Total Assets 334.17
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 408.306
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Armata Pharmaceuticals - ARMP

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
5.51M 4.53M 5.17M 4.90M
Sales Growth
+23.11% -17.77% +14.24% -5.22%
Cost of Goods Sold (COGS) incl D&A
892.00K 972.00K 1.32M 1.53M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
892.00K 972.00K 1.32M 1.53M
Depreciation
892.00K 972.00K 1.32M 1.53M
Amortization of Intangibles
- - - -
-
COGS Growth
- +8.97% +36.32% +15.55%
Gross Income
4.62M 3.56M 3.85M 3.37M
Gross Income Growth
- -22.94% +8.21% -12.37%
Gross Profit Margin
+83.81% +78.54% +74.39% +68.78%
2022 2023 2024 2025 5-year trend
SG&A Expense
41.56M 44.45M 46.28M 34.59M
Research & Development
35.02M 33.77M 34.43M 23.72M
Other SG&A
6.54M 10.68M 11.86M 10.88M
SGA Growth
+53.21% +6.94% +4.14% -25.26%
Other Operating Expense
- - - -
-
Unusual Expense
- 25.71M (33.56M) 126.38M
EBIT after Unusual Expense
(36.95M) (66.60M) (8.87M) (157.60M)
Non Operating Income/Expense
29.00K 179.00K 697.00K 388.00K
Non-Operating Interest Income
29.00K 179.00K 697.00K 388.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 2.63M 10.74M 16.59M
Interest Expense Growth
- -100.00% +309.06% +54.44%
Gross Interest Expense
- 2.63M 10.74M 16.59M
Interest Capitalized
- - - -
-
Pretax Income
(36.92M) (69.05M) (18.92M) (173.80M)
Pretax Income Growth
-59.43% -87.03% +72.60% -818.79%
Pretax Margin
-670.24% -1,524.51% -365.60% -3,544.03%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(36.92M) (69.05M) (18.92M) (173.80M)
Minority Interest Expense
- - - -
-
Net Income
(36.92M) (69.05M) (18.92M) (173.80M)
Net Income Growth
-59.43% -87.03% +72.60% -818.79%
Net Margin Growth
-670.24% -1,524.51% -365.60% -3,544.03%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(36.92M) (69.05M) (18.92M) (173.80M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(36.92M) (69.05M) (18.92M) (173.80M)
EPS (Basic)
-1.0765 -1.9139 -0.5231 -4.7959
EPS (Basic) Growth
-12.07% -77.79% +72.67% -816.82%
Basic Shares Outstanding
34.29M 36.08M 36.16M 36.24M
EPS (Diluted)
-1.0765 -1.9139 -0.5231 -4.7959
EPS (Diluted) Growth
-12.07% -77.79% +72.67% -816.82%
Diluted Shares Outstanding
34.29M 36.08M 36.16M 36.24M
EBITDA
(36.05M) (39.92M) (41.11M) (29.69M)
EBITDA Growth
-59.16% -10.72% -2.99% +27.78%
EBITDA Margin
-654.58% -881.39% -794.57% -605.44%

Snapshot

Average Recommendation BUY Average Target Price 15.00
Number of Ratings 2 Current Quarters Estimate -0.39
FY Report Date 06 / 2026 Current Year's Estimate -1.15
Last Quarter’s Earnings -0.38 Median PE on CY Estimate N/A
Year Ago Earnings -4.80 Next Fiscal Year Estimate -0.93
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate -0.39 -0.23 -1.15 -0.93
High Estimates -0.39 -0.23 -1.15 -0.93
Low Estimate -0.39 -0.23 -1.15 -0.93
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Armata Pharmaceuticals in the News